Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Cariprazine (Reagila®) is a once-daily, oral, atypical antipsychotic for the treatment of schizophrenia in adults.
Download the full review below to read more.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.